Details for Patent: 5,376,634
✉ Email this page to a colleague
Summary for Patent: 5,376,634
| Title: | Polypeptide compound and a process for preparation thereof |
| Abstract: | A polypeptide compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or acyl group, R.sup.2 is hydroxy or acyloxy, R.sup.3 is hydroxysulfonyloxy, and R.sup.4 is hydrogen or carbamoyl, with proviso that R.sup.1 is not palmitoyl, when R.sup.2 is hydroxy, R.sup.3 is hydroxysulfonyloxy and R.sup.4 is carbamoyl, and a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Iwamoto; Toshiro (Tsukuba, JP), Fujie; Akihiko (Tsuchiura, JP), Nitta; Kumiko (Tsuchiura, JP), Tsurumi; Yasuhisa (Tsukuba, JP), Shigematsu; Nobuharu (Tsukuba, JP), Kasahara; Chiyoshi (Ikeda, JP), Hino; Motohiro (Tsuchiura, JP), Okuhara; Masakuni (Tsukuba, JP), Sakane; Kazuo (Kawanishi, JP), Kawabata; Kohji (Kawanishi, JP), Ohki; Hidenori (Ikeda, JP) |
| Assignee: | Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP) |
| Application Number: | 07/715,961 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
| Scope and claims summary: | United States Patent 5,376,634, issued in 1994, pertains to a 'Method for Producing Recombinantly Expressed Human Leukocyte Antigen (HLA) Molecules in a Yeast Expression System.' The patent, filed by the Stanford University Research Institution, represents a significant advancement in the field of immunogenetics and has had far-reaching implications for vaccine development and disease research. At its core, the invention revolves around a yeast-based expression system capable of producing human leukocyte antigen (HLA) proteins in sufficient quantities for use in immunological research and medicine. The HLA molecules are essential for the immune system's ability to distinguish between the body's own cells and foreign substances, such as viruses and bacteria. They play a critical role in the development of vaccines and the treatment of various diseases, including cancer and autoimmune disorders. The patent disclosure describes a novel method that utilizes the yeast Saccharomyces cerevisiae as a production platform to express functional HLA proteins. The approach employs a recombinant DNA technique, where the genetic material encoding the HLA gene is introduced into the yeast cells via a microinjection method. This allows for the efficient expression of the HLA proteins, which can be harvested, purified, and used in immunological applications. The claims of the patent span a broad spectrum, including the method of producing HLA molecules in yeast, the recombinant plasmid used to express the HLA gene, and the purified HLA proteins themselves. The patentholder, Stanford University, asserts its rights to these claims, outlining the procedures for licensing and commercialization of the invention. Several key points emerge from an analysis of United States Patent 5,376,634:
|
Drugs Protected by US Patent 5,376,634
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 5,376,634
International Family Members for US Patent 5,376,634
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 125550 | ⤷ Subscribe | |||
| Austria | 143671 | ⤷ Subscribe | |||
| Australia | 651347 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
